Physician
Maritza I. Irizarry MD INC
Maritza I. Irizarry MD INC was paid $8.19M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.
33Billing provider infoMARITZA I. IRIZARRY MD INC
PHOENIX, AZ 85015
PHOENIX, AZ 85015
33aNPI1548273113assigned 08/14/2006
33bProvider typePediatrics Physician
28Total paid$8.19M
24GClaims238,126
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Arizona
Rank by total paid#7 of 235
Median peer was paid$164K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,411 | $1.02M | |
| 2019 | 41,444 | $994K | |
| 2020 | 28,645 | $888K | |
| 2021 | 32,133 | $1.34M | |
| 2022 | 34,828 | $1.51M | |
| 2023 | 33,182 | $1.40M | |
| 2024incomplete | 26,483 | $1.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 43% | 47,486 | 38,912 | $3.52M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 29,803 | 26,077 | $1.54M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.2% | 5,830 | 5,723 | $426K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.9% | 4,946 | 4,863 | $403K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.7% | 12,742 | 12,227 | $386K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.6% | 2,967 | 2,705 | $298K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.1% | 3,479 | 3,394 | $251K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 5,427 | 4,792 | $223K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 2,576 | 2,478 | $175K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 1.6% | 789 | 113 | $128K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.3% | 497 | 463 | $109K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 3,556 | 3,374 | $102K |
70 more codes
| 94760 | <1% | 45,039 | $66K | |
| 92567 | <1% | 4,460 | $57K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,603 | $48K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,667 | $47K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,392 | $47K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 402 | $40K |
| 86580 | <1% | 5,597 | $38K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 292 | $25K |
| 92551 | <1% | 4,884 | $24K | |
| 99188 | <1% | 1,811 | $20K | |
| 99000 | <1% | 5,987 | $19K | |
| 81002 | <1% | 5,860 | $17K | |
| 96127 | <1% | 3,748 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,205 | $15K |
| 96160 | <1% | 6,211 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 596 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 935 | $13K |
| 94664 | <1% | 942 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 255 | $11K |
| 0071A | <1% | 136 | $10K | |
| 93975 | <1% | 43 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 124 | $8K |
| 90461 | <1% | 673 | $8K | |
| 99381 | <1% | 100 | $7K | |
| 0072A | <1% | 76 | $6K | |
| 95117 | <1% | 630 | $5K | |
| 99173 | <1% | 4,177 | $5K | |
| 99382 | <1% | 40 | $3K | |
| 82962 | <1% | 1,069 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 96 | $3K |
| 94010 | <1% | 100 | $3K | |
| 99383 | <1% | 32 | $3K | |
| 0002A | <1% | 54 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 23 | $1K |
| 0001A | <1% | 15 | $1K | |
| 99384 | <1% | 12 | $994.56 | |
| 94761 | <1% | 521 | $788.65 | |
| A7004 | Small volume nonfiltered pneumatic nebulizer, disposable | <1% | 980 | $752.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 456 | $431.06 |
| 95115 | <1% | 45 | $307.25 | |
| 90620 | <1% | 245 | $115.50 | |
| 90686 | <1% | 3,564 | $96.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 269 | $54.11 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 362 | $47.38 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 925 | $41.92 |
| 91300 | <1% | 33 | $0.07 | |
| 90696 | 0% | 25 | $0.00 | |
| 90680 | 0% | 532 | $0.00 | |
| 90698 | 0% | 546 | $0.00 | |
| 90744 | 0% | 180 | $0.00 | |
| 90651 | 0% | 464 | $0.00 | |
| 90688 | 0% | 210 | $0.00 | |
| 90619 | 0% | 61 | $0.00 | |
| 90716 | 0% | 33 | $0.00 | |
| 90674 | 0% | 38 | $0.00 | |
| 90697 | 0% | 17 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 16 | $0.00 |
| 90707 | 0% | 29 | $0.00 | |
| 90633 | 0% | 311 | $0.00 | |
| 90734 | 0% | 539 | $0.00 | |
| 90670 | 0% | 1,257 | $0.00 | |
| 90700 | 0% | 158 | $0.00 | |
| 90713 | 0% | 33 | $0.00 | |
| 90671 | 0% | 60 | $0.00 | |
| 90715 | 0% | 107 | $0.00 | |
| 90649 | 0% | 289 | $0.00 | |
| 90672 | 0% | 163 | $0.00 | |
| 90685 | 0% | 40 | $0.00 | |
| 90710 | 0% | 168 | $0.00 | |
| 90648 | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialIRIZARRY, MARITZA (PRESIDENT)